Arid
DOI10.1001/jama.2010.1320
Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux The FUTURA/OASIS-8 Randomized Trial
Steg, Philippe Gabriel1,2,3; Jolly, Sanjit S.4,5; Mehta, Shamir R.4,5; Afzal, Rizwan4,5; Xavier, Denis6; Rupprecht, Hans-Jurgen7; Lopez-Sendon, Jose L.8; Budaj, Andrzej9; Diaz, Rafael10; Avezum, Alvaro11; Widimsky, Petr12; Rao, Sunil V.13; Chrolavicius, Susan4,5; Joyner, Campbell14; Pogue, Janice4,5; Yusuf, Salim4,5
通讯作者Jolly, Sanjit S.
来源期刊JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
ISSN0098-7484
EISSN1538-3598
出版年2010
卷号304期号:12页码:1339-1349
英文摘要

Context The optimal unfractionated heparin regimen for percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes treated with fondaparinux is uncertain.


Objective To compare the safety of 2 unfractionated heparin regimens during PCI in high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.


Design, Setting, and Participants Double-blind randomized parallel-group trial in 179 hospitals in 18 countries involving 2026 patients undergoing PCI within 72 hours, nested within a cohort of 3235 high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux enrolled from February 2009 to March 2010.


Interventions Patients received intravenously either low-dose unfractionated heparin, 50 U/kg, regardless of use of glycoprotein IIb/IIIa (GpIIb-IIIa) inhibitors or standard-dose unfractionated heparin, 85 U/kg (60 U/kg with GpIIb-IIIa inhibitors), adjusted by blinded activated clotting time (ACT).


Main Outcome Measures Composite of major bleeding, minor bleeding, or major vascular access-site complications up to 48 hours after PCI. Key secondary outcomes include composite of major bleeding at 48 hours with death, myocardial infarction, or target vessel revascularization within day 30.


Results The primary outcome occurred in 4.7% of those in the low-dose group vs 5.8% in the standard-dose group (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.54-1.19; P=.27). The rates of major bleeding were not different but the rates of minor bleeding were lower with 0.7% in the low-dose group vs 1.7% in the standard-dose group (OR, 0.40; 95% CI, 0.16-0.97; P=.04). For the key secondary outcome, the rates for low-dose group were 5.8% vs 3.9% in the standard-dose group (OR, 1.51; 95% CI, 1.00-2.28; P=.05) and for death, myocardial infarction, or target vessel revascularization it was 4.5% for the low-dose group vs 2.9% for the standard-dose group (OR, 1.58; 95% CI, 0.98-2.53; P=.06). Catheter thrombus rates were very low (0.5% in the low-dose group and 0.1% in the standard-dose group, P=.15).


Conclusion Low-dose compared with standard-dose unfractionated heparin did not reduce major peri-PCI bleeding and vascular access-site complications.


类型Article
语种英语
国家France ; Canada ; India ; Germany ; Spain ; Poland ; Argentina ; Brazil ; Czech Republic ; USA
收录类别SCI-E
WOS记录号WOS:000282007900017
WOS关键词ACTIVATED CLOTTING TIME ; EUROPEAN-SOCIETY ; TASK-FORCE ; ANTICOAGULATION ; ENOXAPARIN ; OUTCOMES ; IMPACT
WOS类目Medicine, General & Internal
WOS研究方向General & Internal Medicine
资源类型期刊论文
条目标识符http://119.78.100.177/qdio/handle/2XILL650/164762
作者单位1.INSERM, U Rech Clin Atherothrombose 698, Paris, France;
2.Univ Paris 07, Paris, France;
3.Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France;
4.Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada;
5.McMaster Univ, Hamilton, ON, Canada;
6.St Johns Med Coll, Bangalore, Karnataka, India;
7.Klinikum Russelsheim, Med Klin, Russelsheim, Germany;
8.Hosp Univ La Paz, Dept Cardiol, Madrid, Spain;
9.Grochowski Hosp, Dept Cardiol, Warsaw, Poland;
10.Inst Cardiovasc Rosario, Rosario, Santa Fe, Argentina;
11.Pazzanese Inst Cardiol, Sao Paulo, Brazil;
12.Charles Univ Prague, Med Sch 3, Univ Hosp Vinohrady, Cardioctr, Prague, Czech Republic;
13.Duke Univ, Med Ctr, Durham, NC USA;
14.Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
推荐引用方式
GB/T 7714
Steg, Philippe Gabriel,Jolly, Sanjit S.,Mehta, Shamir R.,et al. Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux The FUTURA/OASIS-8 Randomized Trial[J],2010,304(12):1339-1349.
APA Steg, Philippe Gabriel.,Jolly, Sanjit S..,Mehta, Shamir R..,Afzal, Rizwan.,Xavier, Denis.,...&Yusuf, Salim.(2010).Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux The FUTURA/OASIS-8 Randomized Trial.JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,304(12),1339-1349.
MLA Steg, Philippe Gabriel,et al."Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux The FUTURA/OASIS-8 Randomized Trial".JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 304.12(2010):1339-1349.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Steg, Philippe Gabriel]的文章
[Jolly, Sanjit S.]的文章
[Mehta, Shamir R.]的文章
百度学术
百度学术中相似的文章
[Steg, Philippe Gabriel]的文章
[Jolly, Sanjit S.]的文章
[Mehta, Shamir R.]的文章
必应学术
必应学术中相似的文章
[Steg, Philippe Gabriel]的文章
[Jolly, Sanjit S.]的文章
[Mehta, Shamir R.]的文章
相关权益政策
暂无数据
收藏/分享

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。